Survey Among Healthcare Professionals and MS Patients to Assess Their Understanding of RMP Materials
Recruiting
- Conditions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 335
- Registration Number
- NCT05301907
- Locations
- 🇨🇭
Novartis Investigative Site, Basel, Switzerland
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 51
- Registration Number
- NCT05305664
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany
Health-related Quality of Life, Symptom Severity, and Pain Among Patients With PIK3CA-related Overgrowth Spectrum: A Mixed-methods Observational Study
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT05294289
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
A Post Marketing Surveillance on Piqray in Korea
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 900
- Registration Number
- NCT05293470
- Locations
- 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of
Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 149
- Registration Number
- NCT05285904
- Locations
- 🇨🇭
Novartis Investigative Site, Zurich, Switzerland
Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 140
- Registration Number
- NCT05275868
- Locations
- 🇺🇸
Wash U School of Medicine, Saint Louis, Missouri, United States
🇺🇸Massachusetts General Hospital Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute ., Boston, Massachusetts, United States
First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of EDI048 in Healthy Volunteers
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT05275855
- Locations
- 🇬🇧
Novartis Investigative Site, Mere Way, Nottingham, United Kingdom
A 24-week rPMS Study in Real-world Setting for Enerzair
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 600
- Registration Number
- NCT05274425
- Locations
- 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of
Multiple Ascending Dose Study of MHS552 in Adults With Type 1 Diabetes Mellitus
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05272059
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 105
- Registration Number
- NCT05269966
- Locations
- 🇮🇳
Novartis Investigative Site, New Delhi, India
© Copyright 2024. All Rights Reserved by MedPath